ASTRAZENECA GOSERELIN goserelin 3.6mg (as acetate) implant syringe

Land: Australia

Språk: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv ingrediens:

goserelin, Quantity: 3.6 mg

Tilgjengelig fra:

AstraZeneca Pty Ltd

INN (International Name):

Goserelin

Legemiddelform:

Implant

Sammensetning:

Excipient Ingredients: polyglactin

Administreringsrute:

Subcutaneous

Enheter i pakken:

single syringe

Resept typen:

(S4) Prescription Only Medicine

Indikasjoner:

Prostate Cancer: Palliative treatment of metastatic or locally advanced prostate cancer, where suitable for hormonal manipulation. Adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. Breast Cancer: Treatment of advanced breast cancer (T3b, T4 or any T with N2, 3 or M plus) in premenopausal women suitable for hormonal manipulation. Adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. Endometriosis: In the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. Uterine Fibroids: In the management of fibroids, ASTRAZENECA GOSERELIN shrinks the lesions and reduces the symptoms, including pain. ASTRAZENECA GOSERELIN also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. It is used as an adjunct to surgery to facilitate the operative technique and reduce operativeblood loss. Endometrial Thinning: Use as an endometrial thinning agent prior to endometrial ablation. Assisted Reproduction: Pituitary down regulation in preparation for controlled ovarian superstimulation.

Produkt oppsummering:

Visual Identification: White to cream-coloured cylindrical pieces of rigid polymeric material.; Container Type: Syringe; Container Material: Plastic; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Autorisasjon status:

Registered

Autorisasjon dato:

2006-08-15